In the project “Target Enriched Antiviral Scaffold (TEAS) Inhibitors of Nipah Virus Replication” the goal is to develop orally active small molecule therapeutic agents targeting the henipavirus N-protein that could be stockpiled for any future pandemic. This project will use target enriched antiviral scaffold technologies to identify inhibitor compounds targeting the N-protein. Compounds will be optimized through medicinal chemistry to improve drug-like properties necessary for antiviral development. The 2-year project is lead by the not-for-profit Community Interest Company (CIC) “Collaborative Community against Coronavirus” which is based in Stevenage, United Kingdom.